Postherpetic neuralgia

New England Journal of Medicine

Volumn 371, Issue 16, 2014, Pages 1526-1533

  Johnson, Robert W ^a   Rice, Andrew S C ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIVIRUS AGENT; BUPIVACAINE; CAPSAICIN; DESIPRAMINE; GABAPENTIN; LIDOCAINE; LIVE VACCINE; METHYLPREDNISOLONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VARICELLA ZOSTER VACCINE; 4 AMINOBUTYRIC ACID; AMINE; ANTIPYRETIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRUG DERIVATIVE; LOCAL ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT;

ALLODYNIA; ANALGESIA; ANALGESIA (SENSORY DYSFUNCTION); ANAMNESIS; APPLICATION SITE PAIN; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; BODY WEIGHT DISORDER; BURNING SENSATION; CHRONIC PAIN; CLINICAL FEATURE; CONSTIPATION; DERMATOME; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHEMA; EVIDENCE BASED MEDICINE; EXCORIATION; HERPES ZOSTER; HUMAN; META ANALYSIS (TOPIC); MOOD DISORDER; NAUSEA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE PAIN; NOCICEPTIVE STIMULATION; OFF LABEL DRUG USE; PARESTHESIA; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SCAR FORMATION; SCRATCHING; SEIZURE; SKIN INJURY; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TACTILE STIMULATION; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VACCINATION; VIGNETTE; VOMITING; XEROSTOMIA; ZOSTER BRIEF PAIN INVENTORY; AGED; FEMALE; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; AMINES; ANALGESICS, OPIOID; ANESTHETICS, LOCAL; ANTIPYRETICS; CAPSAICIN; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; LIDOCAINE; NEURALGIA, POSTHERPETIC;

EID: 84908073872     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1403062     Document Type: Article

References (51)

1. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20:748-53.
2. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population- based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9. [Erratum, Mayo Clin Proc 2008;83:255.]
3. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain 2011;152:2204-5.
4. Watson CPN, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991; 44:105-17.
5. Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol 1998;44:789-95.
6. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010;150:12-6.
7. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
8. van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006;367:219-24.
9. van Wijck AJ. Postherpetic neuralgia. (Ph.D. thesis. Utrecht, the Netherlands: Utrecht University, 2006.)
10. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137:38-47.
11. Drolet M, Brisson M, Schmader K, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010;11:1211-21.
12. Balfour HH Jr. Varicella zoster virus infections in immunocompromised hosts: a review of the natural history and management. Am J Med 1988;85:68-73.
13. Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, Rice AS. Comparison of psychological and physical function in neuropathic pain and nociceptive pain: implications for cognitive behavioral pain management programs. Eur J Pain 2008;12:731-41.
14. Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010;26:656-66.
15. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27.
16. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19.
17. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptorsand deafferentation. Neurobiol Dis 1998;5:209-27.
18. Haanpää ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med 2009;122: Suppl:S13-S21.
19. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-56.
20. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitativesystematic review. PLoS Med 2005; 2(7):e164.
21. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51.
22. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013;2:CD007393.
23. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev 2013;11:CD010567.
24. Opioids for persistent pain: good practice. London: British Pain Society, 2010 (http://www.britishpainsociety.org/book-opioid-main.pdf).
25. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
26. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408.
27. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2012;9:CD010111.
28. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;12:CD008242.
29. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4: CD007938.
30. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150: 573-81.
31. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev 2013;8:CD006146.
32. Schmader KE, Baron R, Haanpää ML, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc 2010;85:Suppl:S26-S32.
33. Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 2009;143:169-71.
34. Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 2013;154:2249-61.
35. Lewith GT, Field J, Machin D. Acupuncture compared with placebo in postherpetic pain. Pain 1983;17:361-8.
36. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000;343:1514-9.
37. Nelson DA, Landau WM, Lampe JB, et al. Intrathecal methylprednisolone for postherpetic neuralgia. N Engl J Med 2001;344:1019-22.
38. Rijsdijk M, van Wijck AJ, Meulenhoff PC, Kavelaars A, van der Tweel I, Kalkman CJ. No beneficial effect of intrathecal methylprednisolone acetate in postherpetic neuralgia patients. Eur J Pain 2013;17:714-23.
39. Petersen KL, Rowbotham MC. Relief of post-herpetic neuralgia by surgical removal of painful skin: 5 years later. Pain 2007;131:214-8.
40. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebocontrolled trials. Clin Infect Dis 1996; 22:341-7.
41. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.
42. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:376-83.
43. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997;13:327-31.
44. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50- 59 years. Clin Infect Dis 2012;54:922-8.
45. Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebocontrolled phenotype-stratified study. Pain 2014 August 17 (Epub ahead of print).
46. Ballantyne JC, Stannard C. New addiction criteria: diagnostic challenges persist in treating pain with opioids. IASP Pain Clinical Updates 2013;21:1-7.
47. Thomas BM, Farquhar-Smith P. Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults. Ther Clin Risk Manag 2013;9: 469-75.
48. Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. London: National Institute for Health and Care Excellence, 2013 (http://guidance.nice.org.uk/CG173).
49. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.
50. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
51. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:Suppl:S3-S14.